You are here

Article Text

Article menu
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia
  1. D Dressler1,
  2. F Adib Saberi2
  1. 1
    Rostock University, Gehlsheimer Street 20, Rostock, D-18147, Germany
  2. 2
    Klinikum Nord.Heidberg, Department of Neurology, Tangstedter Landstr. 400, Hamburg, D-22417, Germany
  1. dirk.dressler{at}med.uni-rostock.de

Summary

Botulinum toxin is used with remarkable success to treat various muscle and exocrine gland hyperactivity syndromes. Rarely, treatment failure due to formation of botulinum toxin antibodies (ABF) occurs. To reduce the risk of ABF, a new formulation of Botox (in the following “current Botox”; Allergan, Irvine, California, USA) with increased specific biological potency was introduced. Here we report the case of a 50-year-old woman who developed ABF despite receiving current Botox.

https://doi.org/10.1136/bcr.08.2008.0611

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.